The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
AACR 2017: Poster LB-081/6 – RUNX1- targeted therapy for AML with RUNX1 mutation
A late breaking research poster session titled “Molecular and Cellular Biology 2” took place at the 107th American Association for Cancer Research (AACR) annual meeting in Washington, DC, USA, on Monday 3rd April. During this session, Mill et al. from the MD Anderson Cancer Center displayed their poster (LB-081/6) titled “Novel and effective RUNX1-targeted therapy for AML expressing RUNX1 mutation”.
Somatic mutations in RUNX1 (mtRUNX1) are associated with resistance to standard chemotherapy and poor prognosis in Acute Myeloid Leukemia (AML) patients. Mill et al. aimed to develop a novel targeted therapy for AML expressing mtRUNX1.
The key results were:
- In OCI-AML5 cells (mutant RUNX1 AML cell line), shRNA depletion of RUNX1 led to an attenuation of RUNX1 target gene expression, inhibition of cell proliferation, and an increase in apoptosis
- Depletion of Bromodomain-Containing Protein 4 (BRD4) in OCI-AML5 cells led to a decrease in RUNX1 expression, inhibition of cell proliferation, and an increase in apoptosis
- OTX015 (Bromodomain and Extra-Terminal [BET] Protein [BETP] inhibitor) reduced BRD4 occupancy at the enhancer and promoter of RUNX1 in OCI-AML5 cells
- Treatment of NSG mice engrafted with luciferase-transduced OCI-AML5 cells with OTX015 reduced the AML burden and significantly improved their survival (P < 0.01)
- Co-treatment with the OTX015 and ABT-199 (BCL2 inhibitor) or palbociclib (CDK4/6 inhibitor) or decitabine synergistically induced apoptosis of OCI-AML5 and PD AML BPCs
In summation, BETP antagonist-based therapy for AML expressing mtRUNX1 was effective either alone or in combination therapy.
References